Frankfurt - Delayed Quote EUR

Soleno Therapeutics, Inc. (6XC.F)

65.85

+1.80

+(2.81%)

As of 9:59:01 AM GMT+2. Market Open.

Soleno Therapeutics Announces Oral Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at ESPE and ESE 2025

REDWOOD CITY, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will present data from its VYKATTM XR (diazoxide choline) extended-release tablets, previously referred to as DCCR, clinical development program for the treatment of hyperphagia associated with Prader-Willi syndrome (PWS) at the Joint Congress of European Society for Pediatri

GlobeNewswire 16 hours ago

SLNO
Soleno Therapeutics Inc (SLNO) Q1 2025 Earnings Call Highlights: Navigating Early Success and ...

Soleno Therapeutics Inc (SLNO) reports a strong initial market response to Vykat XR despite a significant net loss and high operational expenses in Q1 2025.

GuruFocus.com yesterday

SLNO
Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports First Quarter 2025 Financial Results

REDWOOD CITY, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided an update on the U.S. launch of VYKATTM XR and reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 and Recent Corporate Highlights Announced U.S. Food and Drug Administration (FDA) approval of VYKAT XR (diazoxide choline) extended-release tablets,

GlobeNewswire yesterday

SLNO
Soleno Therapeutics (SLNO) is on the Move, Here's Why the Trend Could be Sustainable

Soleno Therapeutics (SLNO) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Zacks 2 days ago

SLNO
Exploring High Growth Tech Stocks In The US Market

The United States market has experienced a positive trajectory, climbing 2.2% in the last 7 days and showing an 8.2% increase over the past year, with earnings forecasted to grow by 14% annually. In this context of robust growth, identifying high-growth tech stocks involves evaluating companies that demonstrate strong innovation potential and scalability within these favorable market conditions.

Simply Wall St. 3 days ago

ARQT

SLNO

OLO
Soleno Therapeutics to Report First Quarter 2025 Financial Results and Host Inaugural Quarterly Conference Call on May 7, 2025, at 4:30 PM ET

REDWOOD CITY, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will report its first quarter 2025 financial results, as well as operational highlights, after the close of the U.S. financial markets on Wednesday, May 7, 2025. The Company will host a conference call and webcast at 4:30 PM Eastern Time to discuss the results and provide

GlobeNewswire 16 days ago

SLNO
Soleno Therapeutics Announces VYKAT(TM) XR Launch

First prescriptions delivered to individuals with PWSREDWOOD CITY, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the U.S. commercial availability of VYKAT™ XR (diazoxide choline) extended-release tablets, the company’s treatment for hyperphagia in patients four years of age and older with Prader-Willi syndrome (PWS), which was approved by t

GlobeNewswire 25 days ago

SLNO
High Growth Tech Stocks To Watch In The US April 2025

Over the last 7 days, the United States market has dropped 3.4%, yet it remains up by 6.1% over the past year, with earnings anticipated to grow by 14% annually in the coming years. In this context, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation potential and resilience amidst fluctuating market conditions.

Simply Wall St. last month

VRRM

SLNO

ABBV
Why Soleno Therapeutics Inc. (SLNO) Went Up Last Week?

We recently published a list of 10 Stocks Outperform Broader Market Last Week. In this article, we are going to take a look at where Soleno Therapeutics Inc. (NASDAQ:SLNO) stands against other stocks that outperformed broader market last week. Wall Street’s main indices traded lower week-on-week as investor sentiment continued to be dragged by the […]

Insider Monkey last month

SLNO

^GSPC
Why Soleno Therapeutics Inc. (SLNO) Went Up On Friday?

We recently published a list of 10 Firms End Friday Strong; 3 Reach All-Time Highs. In this article, we are going to take a look at where Soleno Therapeutics Inc. (NASDAQ:SLNO) stands against other firms that end Friday strong. Wall Street’s main indices finished the trading week in the negative territory as investor sentiment was […]

Insider Monkey last month

SLNO

^GSPC
Why Soleno Therapeutics Inc. (SLNO) Surged On Thursday?

We recently published a list of 10 Stocks Jump, Defy Market Uncertainties on Thursday. In this article, we are going to take a look at where Soleno Therapeutics Inc. (NASDAQ:SLNO) stands against other stocks that jumped, defying market uncertainties on Thursday. The stock market extended losses on Thursday, with all the major indices ending in […]

Insider Monkey last month

SLNO

^GSPC
Soleno Surges Into Breakout On Hard-Won Obesity-Tied Approval, But Aardvark Reverses Lower

Soleno Therapeutics won approval for a drug that treats excessive hunger associated with a rare disease, and the biotech stock rocketed.

Investor's Business Daily last month

AARD

SLNO
Soleno wins FDA approval for Prader-Willi hyperphagia treatment

The drug, named Vykat XR, will be available to patients in the US with Prader-Willi syndrome from April 2025.

Pharmaceutical Technology last month

SLNO

GLDAF
Soleno stock skyrockets on FDA drug approval

Soleno Therapeutics (SLNO) stock is skyrocketing after the company received FDA approval for its new drug to treat excessive hunger for patients with Prader-Willi syndrome. Wealth host Brad Smith is joined by Yahoo Finance's Julie Hyman to discuss the stock's movement. To watch more expert insights and analysis on the latest market action, check out more Wealth here.

Yahoo Finance Video last month

SLNO
SLNO Stock Rallies on FDA Approval of Prader-Willi Syndrome Drug

Soleno's shares soar in the premarket hours following the FDA approval of Vykat XR (diazoxide choline) for treating hyperphagia in PWS patients.

Zacks last month

SLNO
Soleno Therapeutics Announces U.S. FDA Approval of VYKATTM XR to Treat Hyperphagia in Prader-Willi Syndrome

First approved therapy to address hyperphagia in individuals with Prader-Willi syndrome Management to host conference call and webcast today, March 26th, at 5:30pm ET REDWOOD CITY, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved VYKAT XR (diazoxide choline) extended-release tablets, previou

GlobeNewswire last month

SLNO
Exploring US High Growth Tech Stocks In March 2025

Over the last 7 days, the United States market has experienced a slight decline of 1.3%, yet it has shown resilience with a 15% increase over the past year and earnings forecast to grow by 14% annually. In this dynamic environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation potential and adaptability to sustain growth amidst fluctuating market conditions.

Simply Wall St. 2 months ago

SLNO

NOW

ASND
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results

REDWOOD CITY, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the fourth quarter and full-year ended December 31, 2024. Full Year 2024 and Recent Corporate Highlights Regulatory New Drug Application (NDA) for diazoxide choline extended-release tablets (DCCR) for the treatment of Prader-Will

GlobeNewswire 2 months ago

SLNO
Soleno Therapeutics to Participate in Upcoming February Investor Conferences

REDWOOD CITY, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will participate in the following investor conferences in February: Guggenheim SMID Cap Biotech ConferencePresentation Date: Thursday, February 6, 2025 at 2:00 PM ETPresentation Format: Fireside ChatWebcast: https://wsw.com/webcast/guggen2/slno/2028708 Oppen

GlobeNewswire 3 months ago

SLNO
High Growth Tech Stocks to Watch in January 2025

Over the last week, the United States market saw a 3.1% increase, contributing to a 24% climb over the past year, with earnings forecasted to grow by 15% annually. In this environment of robust growth, identifying high-growth tech stocks that align with these optimistic projections can be crucial for investors looking to capitalize on emerging opportunities in this dynamic sector.

Simply Wall St. 3 months ago

KRYS

LEGN

SLNO

Performance Overview

Return	6XC.F	S&P 500 (^GSPC)
YTD	+57.08%	-3.70%
1-Year	+89.33%	+8.63%
3-Year	+2,714.10%	+41.91%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Soleno Therapeutics, Inc. (6XC.F)

Soleno Therapeutics Announces Oral Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at ESPE and ESE 2025

Soleno Therapeutics Inc (SLNO) Q1 2025 Earnings Call Highlights: Navigating Early Success and ...

Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports First Quarter 2025 Financial Results

Soleno Therapeutics (SLNO) is on the Move, Here's Why the Trend Could be Sustainable

Exploring High Growth Tech Stocks In The US Market

Soleno Therapeutics to Report First Quarter 2025 Financial Results and Host Inaugural Quarterly Conference Call on May 7, 2025, at 4:30 PM ET

Soleno Therapeutics Announces VYKAT(TM) XR Launch

High Growth Tech Stocks To Watch In The US April 2025

Why Soleno Therapeutics Inc. (SLNO) Went Up Last Week?

Why Soleno Therapeutics Inc. (SLNO) Went Up On Friday?

Why Soleno Therapeutics Inc. (SLNO) Surged On Thursday?

Soleno Surges Into Breakout On Hard-Won Obesity-Tied Approval, But Aardvark Reverses Lower

Soleno wins FDA approval for Prader-Willi hyperphagia treatment

Soleno stock skyrockets on FDA drug approval

SLNO Stock Rallies on FDA Approval of Prader-Willi Syndrome Drug

Soleno Therapeutics Announces U.S. FDA Approval of VYKATTM XR to Treat Hyperphagia in Prader-Willi Syndrome

Exploring US High Growth Tech Stocks In March 2025

Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results

Soleno Therapeutics to Participate in Upcoming February Investor Conferences

High Growth Tech Stocks to Watch in January 2025

Performance Overview